Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30001924 | 1.00 | HSD17B10 (0.56) | HSD17B10TSHRKMT2AALDH1A1CYP1A2 | |
| SCHEMBL4014324 | 0.90 | HSD17B10 (0.53) | HSD17B10TSHRKMT2AALDH1A1CYP1A2 | |
| SCHEMBL4513003 | 0.86 | HSD17B10 (0.56) | HSD17B10TSHRKMT2AALDH1A1CYP1A2 | |
| SCHEMBL844111 | 0.86 | HSD17B10 (0.60) | HSD17B10KMT2AALDH1A1CYP1A2VCAM1 | |
| SCHEMBL6295397 | 0.84 | TSHR (0.58) | HSD17B10TSHRKMT2AALDH1A1CYP1A2 | |
| SCHEMBL23883005 | 0.83 | HSD17B10 (0.56) | HSD17B10KMT2AALDH1A1CYP1A2VCAM1 | |
| SCHEMBL2595412 | 0.83 | HSD17B10 (0.56) | HSD17B10KMT2AALDH1A1CYP1A2VCAM1 | |
| SCHEMBL11369484 | 0.83 | HSD17B10 (0.56) | HSD17B10KMT2AALDH1A1VCAM1PDE7A | |
| SCHEMBL30002362 | 0.83 | HSD17B10 (0.56) | HSD17B10KMT2AALDH1A1CYP1A2VCAM1 | |
| SCHEMBL28239875 | 0.83 | HSD17B10 (0.56) | HSD17B10KMT2AALDH1A1CYP1A2VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026077418-A9 | ISOINDOLINE COMPOUND CONTAINING PHENYLETHOXYALKYLENEAMINE STRUCTURE, CONJUGATE THEREOF, AND USE THEREOF | 上海海雁医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20250361234-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250144230-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | ORUM THERAPEUTICS, INC. (KR) | 2025-05-08 | — | — | US | disclosed |
| EP-4536637-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Nico Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20250090681-A1 | NEODEGRADER CONJUGATES | ORUM THERAPEUTICS INC (KR) | 2025-03-20 | — | — | US | disclosed |
| US-20240252671-A1 | NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES | ORUM THERAPEUTICS INC (KR) | 2024-08-01 | — | — | US | disclosed |
| EP-4398942-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | Orum Therapeutics Inc. (KR) | 2024-07-17 | — | — | EP | disclosed |
| CN-118201642-A | Linker for antibody drug conjugates | 奥隆制药 | 2024-06-14 | — | — | CN | disclosed |
| CN-118201641-A | Novel degradant-anti-CD 33 antibody conjugates | 奥隆制药 | 2024-06-14 | — | — | CN | disclosed |
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| WO-2011141716-A2 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2011-11-17 | — | — | WO | disclosed |
| US-6790865-B2 | 2-HYDROXY-2-(4-HYDROXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENOXY OR IMINO)-2-METHYLPROPIONIC ACID DERIVATIVE EXCELLENT BETA 3-ADRENOCEPTOR STIMULANTS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| EP-1072583-B1 | 2-METHYLPROPIONIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-6696489-B1 | PHENOLIC AND PHENYLAMINO SUBSTITUENTS; BETA 3-ADRENOCEPTOR AGONISTS; OBESITY, HYPERGLYCEMIA, INTESTINAL HYPERMOTILITY, POLLAKIURIA, URINARY INCONTINENCE, DEPRESSION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| EP-1043308-B1 | PHENYLAMINOALKYLCARBOXYLIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-20030166719-A1 | 2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)phenoxy or imino)-2-methylpropionic acid derivative excellent beta 3-adrenoceptor stimulants | KISSEI PHARMACEUTICAL CO., LTD. | 2003-09-04 | — | — | US | disclosed |
| US-6353025-B1 | COMPOUNDS AS DRUGS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| EP-1072583-A1 | 2-METHYLPROPIONIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2001-01-31 | — | — | EP | disclosed |
| EP-1043308-A1 | PHENYLAMINOALKYLCARBOXYLIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090681-A1 | NEODEGRADER CONJUGATES | CD44, FOLR1, CD47 | HSD17B10 1567/4885TSHR 1338/4885KMT2A 2917/4885 |
| US-20240252671-A1 | NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES | NEU3, FCGR3B, ENTPD3 | HSD17B10 2571/4885TSHR 713/4885KMT2A 2655/4885 |
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | CSNK1A1, FRK, CSNK1E | HSD17B10 2176/4885TSHR 1074/4885KMT2A 1629/4885 |
| US-20250361234-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SARM1, SARS1, TIAM1 | HSD17B10 3635/4885TSHR 4280/4885KMT2A 3835/4885 |
| US-20030166719-A1 | 2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)phenoxy or imino)-2-methylpropionic acid derivative excellent beta 3-adrenoceptor stimulants | ADRB1, ADRB2, ADRA2A | HSD17B10 542/4885TSHR 1083/4885KMT2A 1886/4885 |
| US-20250144230-A1 | LINKERS FOR USE IN ANTIBODY DRUG CONJUGATES | CD2BP2, CD47, EPCAM | HSD17B10 3930/4885TSHR 2670/4885KMT2A 1804/4885 |
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | HSD17B10 658/4885TSHR 2158/4885KMT2A 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.